Appendix B. Sources of evidence considered by the Committee

Appendix B. Sources of evidence considered by the Committee

The following documentation and opinion were made available to the Committee:

A. Assessment Report prepared by the NHS Centre for Reviews and Dissemination, University of York An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced ovarian cancer, March 2002.

B. Manufacturer/sponsor submissions:

  • Bristol-Myers Squibb

C. Professional/specialist and patient group submissions:

  • CancerBACUP

  • Ovacome

  • Marie Curie Cancer Care

  • MRC Clinical Trials

  • National Cancer Research Institute (formerly UKCCCR)

  • Royal College of Obstetricians and Gynaecologists

D. External expert and patient advocate submissions:

  • Dr Martin Gore, Consultant Oncologist, Royal Marsden Hospital, London

  • Dr Ganesan, Consultant Medical Oncologist, ICRF Medical Oncology Unit, Oxford Radcliffe Hospital, Oxford

  • Louise Bayne, Chair, Ovacome

  • Martin Ledwick, Senior Cancer Information Specialist, CancerBACUP

  • Joanne Rule, Chief Executive, CancerBACUP